Analyst Andrew Berens from Leerink Partners maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report) and keeping the price target at $22.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Andrew Berens has given his Buy rating due to a combination of factors that highlight Aura Biosciences Inc’s promising developments and strategic advancements. The company is making significant progress in its Phase 3 CoMpass trial for bel-sar in early-stage choroidal melanoma, with a notable increase in patient enrollment, suggesting robust interest and potential for successful trial completion by the end of 2025. Additionally, Aura Biosciences is expanding the scope of its Phase 2 choroidal metastases trial to include a broader range of solid tumors, which could enhance the trial’s applicability and impact.
Moreover, the company is advancing its preclinical work for ocular surface cancers and plans to initiate a Phase 1 trial in 2025, demonstrating a commitment to broadening its therapeutic pipeline. In the realm of bladder cancer, Aura is actively enrolling patients to evaluate bel-sar’s efficacy in preventing tumor recurrence, with initial data expected by the end of 2025. The recent patent application for a new formulation of bel-sar designed for bladder cancer treatment further underscores the company’s innovative approach. Coupled with a successful $75 million capital raise, these strategic initiatives form the basis for Berens’s positive outlook on the company’s stock.
In another report released on May 16, Scotiabank also maintained a Buy rating on the stock with a $23.00 price target.